Dr. Klasko is an author, an entrepreneur and a believer in the creative and optimistic transformation of healthcare and higher education. He has been a CEO of two multibillion-dollar health systems, a university president, and a dean of two highly-ranked medical colleges. Currently, he is pursuing his passion to bridge academic health centers with the emerging world of digital medicine and innovation. As President of Thomas Jefferson University, he directed a merger between an almost two-century-old health science university and a nationally ranked university for design and architecture, heralded by the Chronicle of Higher Education as one of the “few successful mergers between academic entities.” As CEO of Jefferson Health, he presided over the growth of the system from $1.5 billion to $9 billion including the acquisition of Health Partners Plan, making Jefferson the first integrated delivery and financial system in Philadelphia history. His most recent book, Feelin’ Alright: How the Message in the Music Can Make Healthcare Healthier uses music and creativity to tackle some of the thorniest issues in healthcare and health equity through radical collaboration, radical communication and radical creativity. His fifth book (with Hemant Taneja of General Catalyst) in 2021, UnHealthcare: A Manifesto for Health Assurance has become the manual for both founders and health system CEOs for bringing together the venture capital world with the traditional healthcare ecosystem and has been translated in several languages. Dr. Klasko serves as an Executive in Residence at General Catalyst, North American ambassador for Sheba Medical Center in Israel, and as CMO and Operating Partner of Abundant Venture Partners. He is also the lead independent director of Teleflex (TFX:NYSE), a $15 billion medical device company. In 2022, President Biden appointed him as a director to the National Board of Education Sciences.

Dr. Taylor-Cousar is a tenured Professor of Internal Medicine and Pediatrics at National Jewish Health where she cares for children with pulmonary disease and adults with Cystic Fibrosis. She was appointed as the Medical Director of Clinical Research Services for NJH in July 2017 and is currently the President of the Medical Staff. She is also the Co-Director of the Adult CF clinical program and the Director of CF Therapeutics Development Network research for the adult CF program. Her expertise is in clinical trial design and conduct, and therapeutic development for the treatment of CF lung disease. She is also actively evaluating the etiology and treatment of lung disease in orangutans (97% genetic homology with humans).

Anne Holland is Professor of Physiotherapy and Head of Respiratory Research at Monash University and Alfred Health in Melbourne, Australia. She leads a research program investigating non-pharmacological treatments for chronic lung disease. Anne is an NHMRC Leadership Fellow and President of the TSANZ.